117 related articles for article (PubMed ID: 37267432)
1. Male Sex Is Not a Risk Factor for Prognosis in Postoperative Thyroid Cancer Patients: A Propensity Score Matching Study.
Zhou Y; Wang Y; Zhang Z; Yin X; Liu J; Zheng W
J Clin Endocrinol Metab; 2023 Nov; 108(12):3330-3337. PubMed ID: 37267432
[TBL] [Abstract][Full Text] [Related]
2. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
Pan M; Li Z; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
[TBL] [Abstract][Full Text] [Related]
3. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study.
Zhang Y; Wang C; Zhang X; Li H; Li X; Lin Y
Endocrine; 2018 Dec; 62(3):655-662. PubMed ID: 30145748
[TBL] [Abstract][Full Text] [Related]
4. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
5. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract][Full Text] [Related]
6. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
7. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of
Zheng W; Rui Z; Wang X; Li N; Tan J; Liu W
Front Endocrinol (Lausanne); 2021; 12():601960. PubMed ID: 34177793
[TBL] [Abstract][Full Text] [Related]
8. Analysis of correlation factors influencing the outcome of initial 131I remnant ablative therapy in intermediate- to high-risk patients with papillary thyroid microcarcinoma.
Wu R; Liu W; Li N; Wang X; Sun D; Ji Y; Jia Q; Tan J; Zheng W
Nucl Med Commun; 2022 Jun; 43(6):669-674. PubMed ID: 35351838
[TBL] [Abstract][Full Text] [Related]
9. Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer.
Bandeira L; Padovani RDP; Ticly AL; Cury AN; Scalissi NM; Marone MMS; Ferraz C
Arch Endocrinol Metab; 2017 Dec; 61(6):590-599. PubMed ID: 29412384
[TBL] [Abstract][Full Text] [Related]
10. Preablative Stimulated Thyroglobulin Levels Can Predict Malignant Potential and Therapeutic Responsiveness of Subcentimeter-Sized, 18F-fluorodeoxyglucose-Avid Cervical Lymph Nodes in Patients With Papillary Thyroid Cancer.
Kwon SY; Kim J; Jung SH; Chong A; Song HC; Bom HS; Min JJ
Clin Nucl Med; 2016 Jan; 41(1):e32-8. PubMed ID: 26164179
[TBL] [Abstract][Full Text] [Related]
11. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
12. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic
Trevizam PG; Tagliarini JV; Castilho EC; de Alencar Marques M; Kiy Y; Mazeto GMFS
Endocr Res; 2017 Feb; 42(1):42-48. PubMed ID: 27144920
[TBL] [Abstract][Full Text] [Related]
13. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.
Nóbrega G; Cavalcanti M; Leite V; Vilar L; Brandão SCS
Endocrine; 2022 Jun; 76(3):642-647. PubMed ID: 35237910
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-risk thyroid carcinoma: indicators of a poor prognosis.
Faro FN; Bezerra ÂMLB; Scalissi NM; Cury AN; Marone MM; Ferraz C; do Prado Padovani R
Arch Endocrinol Metab; 2021 May; 64(6):764-771. PubMed ID: 34033287
[TBL] [Abstract][Full Text] [Related]
15. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
17. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation.
Lin JD; Chao TC; Huang MJ; Weng HF; Tzen KY
Am J Clin Oncol; 1998 Feb; 21(1):77-81. PubMed ID: 9499265
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
[TBL] [Abstract][Full Text] [Related]
19. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study.
Cistaro A; Quartuccio N; Garganese MC; Villani MF; Altini C; Pizzoferro M; Piccardo A; Cabria M; Massollo M; Maghnie M; Campennì A; Siracusa M; Baldari S; Panareo S; Urso L; Bartolomei M; De Palma D; Grossi A; Mazzoletti A; Dondi F; Bertagna F; Giubbini R; Albano D
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1374-1385. PubMed ID: 34664092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
